Skip to content
GLP-1 Calculators

Tirzepatide vs Semaglutide in 2026 — Efficacy, Cost per Pound, and Side-by-Side Data

Direct head-to-head: SURMOUNT and STEP trial efficacy, real 2026 pricing by access path, side-effect profiles, and a clear decision framework.

Updated April 2026

Medical disclaimer: This tool is for informational purposes. Not medical advice. Consult your healthcare provider before starting, stopping, or changing any medication. Drug prices, savings cards, and coverage policies change frequently — verify current pricing directly with the manufacturer or your pharmacy.

Side-by-side at a glance

Key numbers · 2026
Attribute
Tirzepatide
Mounjaro · Zepbound
Semaglutide
Ozempic · Wegovy
Avg body-weight loss (72wk)
Head-to-head trial in adults with obesity, no T2D.
20.2% (SURMOUNT-5)13.7% (SURMOUNT-5)
Avg A1C reduction (max dose)
In Type 2 diabetes patients.
2.1% (SURPASS)1.9% (SUSTAIN)
Receptor mechanism
GLP-1 + GIP (dual)GLP-1 only
List price (2026, monthly)
$1,060 (Zepbound) / $1,080 (Mounjaro)$997 (Ozempic) / $1,349 (Wegovy)
Cash-pay vial program
Self-pay, shipped from manufacturer.
LillyDirect $349 (2.5mg) / $499 (5–15mg)NovoCare $499 (1.7mg, 2.4mg only)
Savings card floor (covered)
$25/month$0–$25/month
Medicare coverage path
T2D (Mounjaro) · OSA (Zepbound)T2D (Ozempic) · CVD/SELECT (Wegovy)
Compounding availability (2026)
Both removed from FDA shortage list late 2024.
Individual necessity onlyIndividual necessity only
Dose titration
2.5 → 15 mg (20 weeks)0.25 → 2.4 mg (16 weeks)
Injection frequency
WeeklyWeekly (Ozempic/Wegovy) · Daily (Saxenda)
Dual agonist
Tirzepatide
Higher average weight loss (~20% at 72 weeks).
LillyDirect vials ($349–$499) make it the cheapest cash-pay branded path.
Mounjaro covers most T2D patients on commercial and Medicare Part D.
Zepbound covers OSA on Medicare — rare win for Medicare weight patients.
Slightly higher GI side-effect rate at max (15mg) dose.
GLP-1 only
Semaglutide
Longer real-world track record (Ozempic since 2017, Wegovy since 2021).
SELECT cardiovascular outcomes data — reduces MACE in T2D + CVD patients.
Wegovy savings card can bring covered copays to $0 (better than Zepbound's $25 floor).
NovoCare vials more limited ($499, only 1.7mg/2.4mg).
Slightly lower GI side-effect rate — often better starting point for needle-averse patients.

Your personalized cost-per-pound comparison

Your inputs

Results

Tirzepatide advantage
13.2 lbs
more loss at 1 year
Semaglutide $/lb lost
$181
Tirzepatide $/lb lost
$143
In head-to-head trials (SURMOUNT-1 vs STEP-1), tirzepatide shows roughly 5-6% more weight loss than semaglutide. Results vary by individual.

The trial data, in plain English

SURMOUNT-5(2024, published in New England Journal of Medicine 2025) is the only published head-to-head trial of tirzepatide vs semaglutide for weight loss. 751 adults with obesity and no T2D were randomized to tirzepatide (max 15mg) or semaglutide (max 2.4mg) for 72 weeks. Mean weight loss: 20.2% with tirzepatide, 13.7% with semaglutide. The tirzepatide arm had roughly 6.5 percentage points more weight loss — for a 220-lb patient, that’s about 14 lbs difference.

SURPASS-2(2021) compared tirzepatide (5, 10, 15mg) to semaglutide 1mg in T2D patients. At 40 weeks, A1C reductions were 2.0%–2.3% for tirzepatide vs 1.9% for semaglutide 1mg. Weight loss: 7.6–11.2 kg for tirzepatide, 5.7 kg for semaglutide. Note: the semaglutide arm used 1mg (standard T2D dose), not 2.4mg (weight-loss maximum), so this trial underestimates semaglutide’s max-dose weight effect.

SELECT (2023, Wegovy) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in adults with established CVD + overweight/obesity — a unique benefit semaglutide has that tirzepatide has not yet demonstrated in a completed outcomes trial.

Cost per pound lost — the number that actually matters

For most patients paying cash or with partial coverage, cost per pound lost is the honest metric. Based on typical 2026 pricing and SURMOUNT-5 efficacy:

  • LillyDirect Zepbound ($499/mo × 18 months) with ~44 lbs loss = $204/lb.
  • NovoCare Wegovy ($499/mo × 18 months) with ~30 lbs loss = $299/lb.
  • Commercial covered + savings card (either drug, ~$25/mo average including card exhaustion): $10–$15/lb.

Run the calculator above with your actual starting weight and access-path pricing. The cost-per-pound gap between tirzepatide and semaglutide is the biggest driver of rational drug choice for cash-pay patients.

Decision framework

  1. Do you have T2D?If yes, explore Mounjaro (tirzepatide) or Ozempic (semaglutide) based on what your plan covers. If your A1C is substantially above goal, tirzepatide’s edge in A1C reduction may matter.
  2. Do you have commercial insurance with AOM coverage?If yes, both Wegovy and Zepbound work. Run the savings-card math for your specific plan — Wegovy’s $0 floor sometimes wins year-one; Zepbound’s higher efficacy may win over 2+ years.
  3. Uninsured or no AOM coverage? Almost always tirzepatide via LillyDirect — both cheaper and more effective than alternatives.
  4. Medicare + established CVD? Wegovy via the SELECT indication is the rare covered path.
  5. Medicare + OSA? Zepbound for OSA is covered. Tirzepatide wins here too.
Related tools
Wegovy vs Zepbound (brand-specific)
Same drugs, weight-loss-only comparison.
Ozempic cost (semaglutide, T2D)
Real 2026 Ozempic pricing.
Zepbound cost (tirzepatide, weight)
Real 2026 Zepbound pricing with LillyDirect.
Weight-loss timeline
Expected pound loss by month on each drug.
Coverage likelihood checker
Which drug is most likely covered for you.
Cost per pound lost
Dollar efficiency across access paths.

Frequently asked questions

Is tirzepatide stronger than semaglutide for weight loss?

Yes, based on SURMOUNT-5 head-to-head data. Tirzepatide (Zepbound) delivered 20.2% average body-weight loss at 72 weeks vs 13.7% for semaglutide (Wegovy) in adults with obesity without T2D. Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1. For a 220-lb patient, that's a difference of about 14 lbs (~44 lbs vs ~30 lbs). Individual response varies — some patients lose more on semaglutide than average. Both are far more effective than older drugs like liraglutide.

Is tirzepatide more expensive than semaglutide?

List prices are close — tirzepatide (Mounjaro $1,080, Zepbound $1,060) is roughly $50–$100/month higher than semaglutide (Ozempic $997, Wegovy $1,349). But real-world access-path pricing favors tirzepatide in 2026: LillyDirect Zepbound vials at $349–$499/month don't have a direct Wegovy equivalent below $499. On cost per pound lost, tirzepatide wins decisively for cash-pay patients. On commercial insurance with savings cards, both tend to $0–$25/month copays.

Which has fewer side effects — tirzepatide or semaglutide?

Broadly similar side-effect profiles — both cause nausea, vomiting, diarrhea, constipation, and fatigue, especially during titration. SURMOUNT-5 data showed slightly higher GI side-effect rates for tirzepatide 15mg than semaglutide 2.4mg, but the difference was modest and most patients tolerated both when titrated slowly. Tirzepatide users sometimes report slightly more early appetite suppression (which patients read as either 'working well' or 'too much'). If you're sensitive to GI side effects, starting with semaglutide and switching if response is inadequate is a common clinical pattern.

Can I switch from semaglutide to tirzepatide?

Yes, with your provider's guidance. Common clinical approach: if you've been on semaglutide 2.4mg for 3+ months and weight loss has plateaued below 10% of starting weight, switching to tirzepatide is supported by evidence. You typically start at tirzepatide 2.5mg (even if you tolerated max semaglutide) because of the different receptor profile, then titrate up over 16–20 weeks. Expect a brief period of nausea during re-titration. Insurance typically allows the switch but may require a new prior auth for tirzepatide.

What about compounded tirzepatide vs compounded semaglutide?

Both molecules were removed from the FDA drug shortage list in late 2024, ending the broad 503A compounding pathway for weight loss. In 2026, legitimate compounded tirzepatide and compounded semaglutide are both restricted to documented individual medical necessity — same regulatory footing. Any telehealth service still mass-marketing either compounded product for general weight loss is operating outside FDA guidance. Verify pharmacy licensing and your documented necessity on file before committing.

Is tirzepatide better for Type 2 diabetes?

Yes, modestly. SURPASS-2 (head-to-head vs semaglutide 1mg for T2D) showed tirzepatide 15mg produced 2.3% A1C reduction vs 1.9% for semaglutide 1mg, with greater weight loss (~12 kg vs ~6 kg). For T2D patients, tirzepatide as Mounjaro is often the first-line GLP-1 choice when A1C is substantially above goal. For patients already well-controlled on semaglutide with meaningful weight loss, switching isn't automatically warranted.

Does insurance cover tirzepatide and semaglutide differently?

Yes. Coverage depends on the branded indication, not the molecule. For T2D: Ozempic (semaglutide) and Mounjaro (tirzepatide) are both well-covered on commercial plans and Medicare Part D. For weight loss: Wegovy (semaglutide) and Zepbound (tirzepatide) face similar commercial AOM coverage limits (~40–50% of large-employer plans). Medicare covers Wegovy only for the SELECT cardiovascular indication; Medicare covers Zepbound only for OSA. Run our insurance coverage checker to estimate your plan.

Which one should I actually pick?

Without T2D and paying cash: Zepbound (tirzepatide) via LillyDirect $499 vials is the cheapest and most effective legal path. Without T2D with commercial AOM coverage: pick based on trial efficacy (tirzepatide edge) and your GI tolerance — either works with a $0–$25 savings-card copay. With T2D: Mounjaro (tirzepatide) usually edges out Ozempic (semaglutide) on efficacy but both are excellent options. On Medicare without cardiovascular disease or OSA: limited options for either class — explore the prior auth guide and VA/Medicaid paths if relevant.

Digital Dashboard Hub

Track your GLP-1 progress, weight loss, and health metrics

DDH has 54 health and wellness trackers — weight loss logs, BMI history, symptom tracking, and habit tools — built for your GLP-1 journey. Free 14-day trial.

Track your GLP-1 journey free →
Part of the Digital Dashboard Hub network
Powered byDigital Dashboard Hub— 250+ free tools

Calculators, trackers, and planners for creators, business, and wellness — all in one place.

Explore all 250+ tools →